AAPG · Ascentage Pharma Group Internat
$19.00
-3.20% last session
End-of-day data · updated 2026-07-29
Market cap
$2B
Enterprise value
$1B
Trailing P/E
—
Forward P/E
-15.4
Dividend yield
—
Beta
0.66
Avg volume
0M
Employees
1K
2D change
-3.20%
5D change
-0.03%
10D change
-2.43%
30D change
3.31%
60D change
-8.62%
MTD change
1.81%
YTD change
-30.32%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — AAPG
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-06-15
Latest call per bank · past 12 months
Recent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-06-15 | BTIG | Reiterates | Buy | $48.00 |
| 2026-06-10 | B. Riley Securities | Initiates | Buy | $0.00 → $45.00 |
| 2026-04-13 | BTIG | Reiterates | Buy | $48.00 |
| 2026-03-26 | BTIG | Reiterates | Buy | $48.00 |
| 2025-12-04 | Oppenheimer | Initiates | Outperform | $0.00 → $45.00 |
| 2025-11-24 | Truist Securities | Initiates | Buy | $0.00 → $51.00 |
| 2025-11-10 | BTIG | Initiates | Buy | $0.00 → $50.00 |
| 2025-11-05 | Piper Sandler | Initiates | Overweight | $0.00 → $48.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-07-28
- RSI (14): RSI is 46 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 1.6% below the 50-day MA ($18.58).
- Price vs 200-day MA: Trading 27.6% below the 200-day MA ($25.26).
- MA cross: The 50-day MA sits below the 200-day MA (death-cross regime) — the longer-term trend points down.
- MACD (12,26,9): MACD histogram is negative (-0.04) — short-term momentum is fading.
- 52-week range: Price is within 10% of the 52-week low ($16.77).
AAPG Price Chart
Loading chart for AAPG…
Fundamentals
About Ascentage Pharma Group Internat
Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company's primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation. It also develops APG-2575, an oral administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors; APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein interactions to treat solid tumors and hematological malignancies; and APG-1252, a small molecule drug to restore apoptosis through dual inhibition of the Bcl-2 and Bcl-xL proteins for the treatment of small-cell lung cancer, non-small cell lung cancer, neuroendocrine tumor, and non-Hodgkin's lymphoma. In addition, the company is developing APG-1387, a small-molecule inhibitor of apoptosis proteins for advanced solid tumors and chronic HBV infection; APG-5918, an orally available and selective embryonic ectoderm development inhibitor. In addition, it is involved in medical research and development; clinical development; clinical trials operations; venture capital investment; rental of buildings; and provision of science and technology promotion services. The company has collaboration relationships with biotechnology and pharmaceutical companies; and research institutions. Ascentage Pharma Group International was founded in 2009 and is headquartered in Suzhou, China.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$124B 8.2% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$73B -9.7% YTD
ARGX
argenx SE
$55B 3.7% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$39B -27.5% YTD
RVMD
Revolution Medicines, Inc.
$39B 130.8% YTD
RPRX
Royalty Pharma plc
$35B 56.7% YTD
ONC
BeOne Medicines Ltd.
$34B 8.8% YTD
INCY
Incyte Corporation
$26B 31.6% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.